QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TSHA

QT44Taysha Gene Therapies, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
6.42
+0.23+3.72%
OverviewShort InterestFilings
TSHAQT44Taysha Gene Therapies, Inc.·NASDAQ
OverviewShort InterestFilings
6.42+3.72%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)-0.36
Insider Own11.98%
Shs Outstand287.36M
Perf Week15.05%
Market Cap1.55BForward P/E-EPS next Y-0.46Insider Trans-0.13%Shs Float-Perf Month23.70%
Enterprise Value1.29BPEG2.60EPS next Q-0.12Inst Own-Short Float-Perf Quarter40.79%
Income-88597031.00P/S207.32EPS this Y-32.05%Inst Trans-Short Ratio-Perf Half Y10.31%
Sales7.47MP/B10.71EPS next Y4.10%ROA-43.24%Short Interest-Perf YTD16.73%
Book/sh0.74P/C-EPS next 5Y-ROE-56.07%52W High7.30 -12.05%Perf Year151.76%
Cash/sh0.96P/FCF-EPS past 3/5Y-ROIC-47.30%52W Low2.25 185.33%Perf 3Y-
Dividend Est.-EV/EBITDA-9.99Sales past 3/5Y49.38% -Gross Margin88.22%Volatility4.99% 4.36%Perf 5Y-
Dividend TTM-EV/Sales172.68EPS Y/Y TTM-5.56%Oper. Margin-1774.37%ATR (14)0.40Perf 10Y-
Dividend Ex-Date-Quick Ratio14.04Sales Y/Y TTM0.00%Profit Margin-1738.40%RSI (14)61.83Recom2.20
Dividend Gr. 3/5Y-Current Ratio14.04EPS Q/Q-50.00%SMA2011.97%Beta1.97Target Price12.00
Payout0.00%Debt/Eq0.08Sales Q/Q-100.00%SMA507.71%Rel Volume2.66Prev Close6.19
Employees73LT Debt/Eq0.07EarningsAug 11SMA20031.46%Avg Volume2.69MPrice6.42
IPO DateSep 24, 2020Option/ShortYes / YesEPS/Sales Surpr.-20.00% -Net Debt/EBITDA2.00Volume7,141,149Change3.72%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-06-26ReiteratedRaymond James$9.00 → $13
Jan-05-26ReiteratedWells FargoOverweight$11
Dec-04-25ReiteratedGoldman SachsNeutral$11
Dec-04-25ReiteratedUBS$11
Nov-14-25ReiteratedCantor FitzgeraldOverweight$44 → $13
Nov-05-25ReiteratedJMP SecuritiesMarket Outperform$6.00 → $8.00
Oct-02-25ReiteratedRobert W. Baird$7.00 → $12
Oct-02-25ReiteratedNeedhamBuy$10
Aug-14-24ReiteratedBMO Capital$5.00
Jul-01-24ReiteratedPiper SandlerOverweight$7.00
Latest News
Jun-17-26
Jun-17-2608:03AM
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue8108
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit8108
Selling, General and Administrative Excl. Other323429
Research and Development668666
Other Operating Expense505
Operating Income-94-110-91
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-1-2-2
Net Income Before Taxes-94-109-89
Income Taxes
000
Consolidated Net Income-94-109-89
Net Income From Continuing Operations-94-109-89
Net Income-94-109-89
EPS (Recurring)-0.36-0.34-0.36
EPS (Basic, Before Extraordinaries)-0.36-0.34-0.36
EPS (Diluted)-0.36-0.34-0.36
EBITDA-91-108-88
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio239.15176.00—
Gross Margin100.00100.00100.00
Operating Margin-1,175.00-1,100.00-1,137.50
Net Margin-1,175.00-1,090.00-1,112.50
Shares Outstanding298320250
Market Capitalization1,9131,760—
Operating Lease Expense
———
Insider Trading Volume
$7.05$6.42$5.79$5.17$4.54● Close Price0.00M0.70M1.41M2.11M2.81MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Nagendran SukumarPresident and Head of R&DApr 10 '26Sale4.46200,000892,0001,136,410Apr 13 12:00 AM
Nagendran SukumarPresident and Head of R&DApr 10 '26Option Exercise1.7138,04265,0521,336,410Apr 13 12:00 AM
Alam KamranCHIEF FINANCIAL OFFICERFeb 04 '26Sale4.521,6557,4811,442,131Feb 06 12:00 AM
Nolan Sean P.Chief Executive OfficerJan 26 '26Sale4.6141,312190,4482,908,257Jan 27 12:00 AM
Nagendran SukumarPresident and Head of R&DJan 26 '26Sale4.6126,918124,0921,317,389Jan 27 12:00 AM
Alam KamranCHIEF FINANCIAL OFFICERJan 26 '26Sale4.6123,849109,9441,443,786Jan 27 12:00 AM
Nolan Sean P.Chief Executive OfficerJan 23 '26Sale4.75136,789649,7482,949,569Jan 27 12:00 AM
Nagendran SukumarPresident and Head of R&DJan 23 '26Sale4.7589,132423,3771,344,307Jan 27 12:00 AM
Alam KamranCHIEF FINANCIAL OFFICERJan 23 '26Sale4.7578,968375,0981,467,635Jan 27 12:00 AM
Nagendran SukumarPresident and Head of R&DJan 12 '26Option Exercise1.15400,000458,8801,206,439Jan 14 12:00 AM
Nagendran SukumarPresident and Head of R&DJan 12 '26Sale4.71200,000942,0001,006,439Jan 14 12:00 AM
Nagendran SukumarPresident and Head of R&DDec 01 '25Option Exercise1.71520,094889,3601,266,486Dec 01 12:00 AM
Nagendran SukumarPresident and Head of R&DDec 01 '25Sale4.51260,0471,172,8121,006,439Dec 01 12:00 AM
Nagendran SukumarPresident and Head of R&DNov 28 '25Sale4.75110,125523,0941,006,439Dec 01 12:00 AM
Nagendran SukumarPresident and Head of R&DNov 28 '25Option Exercise1.07220,250234,7261,116,564Dec 01 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR